Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Linh Nguyen, M.D.

Co-Author

This page shows the publications co-authored by Paul Nguyen and Anthony D'Amico.
Connection Strength

16.224
  1. Toward personalizing the use of androgen deprivation therapy to maximize benefit and minimize harm. Eur Urol. 2015 Sep; 68(3):397-8.
    View in: PubMed
    Score: 0.601
  2. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012 Oct; 188(4):1151-6.
    View in: PubMed
    Score: 0.511
  3. Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):114.
    View in: PubMed
    Score: 0.493
  4. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5.
    View in: PubMed
    Score: 0.485
  5. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011 Jan 15; 117(2):406-13.
    View in: PubMed
    Score: 0.446
  6. Deciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Williston Park). 2010 Jul; 24(8):705, 711.
    View in: PubMed
    Score: 0.441
  7. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22.
    View in: PubMed
    Score: 0.439
  8. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
    View in: PubMed
    Score: 0.428
  9. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52.
    View in: PubMed
    Score: 0.421
  10. Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129.
    View in: PubMed
    Score: 0.408
  11. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy. 2009 Oct-Dec; 8(4):345-52.
    View in: PubMed
    Score: 0.407
  12. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):337-41.
    View in: PubMed
    Score: 0.406
  13. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):104-9.
    View in: PubMed
    Score: 0.403
  14. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008 Dec 01; 113(11):3146-52.
    View in: PubMed
    Score: 0.395
  15. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):659-64.
    View in: PubMed
    Score: 0.387
  16. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol. 2008 Apr 20; 26(12):2055-6; author reply 2056-7.
    View in: PubMed
    Score: 0.379
  17. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007 Aug; 70(2):288-93.
    View in: PubMed
    Score: 0.360
  18. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005 May 15; 103(10):2053-9.
    View in: PubMed
    Score: 0.309
  19. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4503.
    View in: PubMed
    Score: 0.292
  20. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol. 2004 Jul-Aug; 22(4):295-9.
    View in: PubMed
    Score: 0.291
  21. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):400-5.
    View in: PubMed
    Score: 0.289
  22. Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited. J Clin Oncol. 2021 09 01; 39(25):2845-2846.
    View in: PubMed
    Score: 0.235
  23. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96. Eur Urol. 2020 11; 78(5):e195.
    View in: PubMed
    Score: 0.223
  24. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 06; 3(3):270-280.
    View in: PubMed
    Score: 0.217
  25. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 2019 Feb 19; 321(7):704-706.
    View in: PubMed
    Score: 0.201
  26. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 08; 16(4):313-317.
    View in: PubMed
    Score: 0.191
  27. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5.
    View in: PubMed
    Score: 0.154
  28. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
    View in: PubMed
    Score: 0.151
  29. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
    View in: PubMed
    Score: 0.150
  30. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
    View in: PubMed
    Score: 0.149
  31. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42.
    View in: PubMed
    Score: 0.149
  32. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
    View in: PubMed
    Score: 0.149
  33. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
    View in: PubMed
    Score: 0.148
  34. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36.
    View in: PubMed
    Score: 0.146
  35. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
    View in: PubMed
    Score: 0.145
  36. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
    View in: PubMed
    Score: 0.145
  37. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View in: PubMed
    Score: 0.145
  38. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9.
    View in: PubMed
    Score: 0.144
  39. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
    View in: PubMed
    Score: 0.144
  40. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
    View in: PubMed
    Score: 0.144
  41. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
    View in: PubMed
    Score: 0.144
  42. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943.
    View in: PubMed
    Score: 0.142
  43. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32.
    View in: PubMed
    Score: 0.140
  44. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6.
    View in: PubMed
    Score: 0.137
  45. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21.
    View in: PubMed
    Score: 0.134
  46. Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82.
    View in: PubMed
    Score: 0.132
  47. Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232.
    View in: PubMed
    Score: 0.132
  48. Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):149.
    View in: PubMed
    Score: 0.132
  49. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
    View in: PubMed
    Score: 0.131
  50. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6.
    View in: PubMed
    Score: 0.125
  51. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int. 2012 Dec; 110(11):1690-5.
    View in: PubMed
    Score: 0.125
  52. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
    View in: PubMed
    Score: 0.125
  53. Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. J Clin Oncol. 2012 Feb 10; 30(5_suppl):38.
    View in: PubMed
    Score: 0.123
  54. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):21-5.
    View in: PubMed
    Score: 0.122
  55. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178.
    View in: PubMed
    Score: 0.120
  56. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6.
    View in: PubMed
    Score: 0.118
  57. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20.
    View in: PubMed
    Score: 0.113
  58. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6.
    View in: PubMed
    Score: 0.111
  59. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010 Nov; 76(5):1201-5.
    View in: PubMed
    Score: 0.111
  60. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol. 2010 May; 183(5):1798-802.
    View in: PubMed
    Score: 0.108
  61. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009 Dec 10; 27(35):6000-5.
    View in: PubMed
    Score: 0.105
  62. The association between overexpression of skp2 and the risk of recurrence following prostatectomy. J Clin Oncol. 2008 May 20; 26(15_suppl):11052.
    View in: PubMed
    Score: 0.095
  63. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007 Oct 01; 110(7):1417-28.
    View in: PubMed
    Score: 0.091
  64. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007 Oct 01; 110(7):1485-92.
    View in: PubMed
    Score: 0.091
  65. Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys. 2022 01 01; 112(1):75-82.
    View in: PubMed
    Score: 0.060
  66. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol. 2021 08; 161:241-250.
    View in: PubMed
    Score: 0.059
  67. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304.
    View in: PubMed
    Score: 0.058
  68. Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy. 2021 Jan-Feb; 20(1):1-9.
    View in: PubMed
    Score: 0.056
  69. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 03 15; 109(4):953-963.
    View in: PubMed
    Score: 0.056
  70. Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncol. 2020 10 01; 6(10):1630-1632.
    View in: PubMed
    Score: 0.056
  71. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724.
    View in: PubMed
    Score: 0.053
  72. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978.
    View in: PubMed
    Score: 0.052
  73. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346.
    View in: PubMed
    Score: 0.051
  74. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol. 2019 06 18; 73(23):2976-2987.
    View in: PubMed
    Score: 0.051
  75. Association of Treatment With 5a-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med. 2019 06 01; 179(6):812-819.
    View in: PubMed
    Score: 0.051
  76. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072.
    View in: PubMed
    Score: 0.051
  77. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10.
    View in: PubMed
    Score: 0.051
  78. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203.
    View in: PubMed
    Score: 0.050
  79. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191.
    View in: PubMed
    Score: 0.050
  80. Reply to Partial gland therapy for prostate cancer. Cancer. 2019 03 01; 125(5):819-820.
    View in: PubMed
    Score: 0.050
  81. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535.
    View in: PubMed
    Score: 0.048
  82. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer. 2018 07 15; 124(14):2939-2947.
    View in: PubMed
    Score: 0.047
  83. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888.
    View in: PubMed
    Score: 0.047
  84. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905.
    View in: PubMed
    Score: 0.047
  85. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20.
    View in: PubMed
    Score: 0.046
  86. ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):437-454.
    View in: PubMed
    Score: 0.044
  87. ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 02; 40(1):1-10.
    View in: PubMed
    Score: 0.044
  88. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276.
    View in: PubMed
    Score: 0.043
  89. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84.
    View in: PubMed
    Score: 0.043
  90. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401.
    View in: PubMed
    Score: 0.038
  91. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
    View in: PubMed
    Score: 0.037
  92. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
    View in: PubMed
    Score: 0.036
  93. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View in: PubMed
    Score: 0.035
  94. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.035
  95. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.033
  96. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.032
  97. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
    View in: PubMed
    Score: 0.031
  98. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15; 116(8):1887-92.
    View in: PubMed
    Score: 0.027
  99. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.